COLLEEN WALTZ CURR: Open Payments
NPI 1992146054 · SYRACUSE, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,308 in 95 payments from 15 companies in 2025. Trend: 2023 $1,530 · 2024 $1,651 · 2025 $2,308
Food & beverage: $2,308
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 14 | $382 |
| ABBVIE INC. | 21 | $375 |
| Teva Pharmaceuticals USA, Inc. | 12 | $368 |
| E.R. Squibb & Sons, L.L.C. | 10 | $255 |
| Supernus Pharmaceuticals, Inc. | 6 | $163 |
| Axsome Therapeutics, Inc. | 5 | $162 |
| Alkermes, Inc. | 6 | $123 |
| Lundbeck LLC | 5 | $113 |
| Vanda Pharmaceuticals Inc. | 4 | $104 |
| Janssen Pharmaceuticals, Inc | 4 | $88 |
Products named: REXULTI, VRAYLAR, UZEDY, COBENFY, Qelbree, Auvelity, ARISTADA, ABILIFY MAINTENA.
Industry payments across NY — which companies pay providers there.
